National Institutes of Health: Thalassemia trials

The registry lists 14 Thalassemia studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 2 have results posted.

Early Phase 1 1Phase 1 3Phase 2 7No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin LabelingRecruitingNCT06313398Early Phase 1
• Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant FailureActive, not recruitingNCT02105766Phase 2Results posted
• Haploidentical PBMC Transplant for Severe Congenital AnemiasActive, not recruitingNCT00977691Phase 1/2Results posted
• Perceptions of Thalassemia Major in Singapore: An Exploratory Study of StigmaCompletedNCT01129076
• Oral Nifedipine to Treat Iron OverloadCompletedNCT00712738Phase 1
• Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or ThalassemiaTerminatedNCT00034528Phase 2
• Cord Blood Transplantation for Sickle Cell Anemia and ThalassemiaCompletedNCT00029380Phase 2
• Diagnostic Pilot Study of Dual Energy Absorptiometry in the Detection of Osteopenia or Osteoporosis in Patients With Thalassemia MajorCompletedNCT00006138
• 5-Azacytidine and Phenylbutyrate to Treat Severe ThalassemiaCompletedNCT00005934Phase 2
• Combination Iron Chelation TherapyCompletedNCT00004982Phase 1
• Stem Cell Transplantation (SCT) for Genetic DiseasesCompletedNCT00004378Not applicable
• Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)CompletedNCT00001958Phase 2
• Deferoxamine for the Treatment of HemochromatosisCompletedNCT00001203
• Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional HemochromatosisCompletedNCT00000595Phase 2